MARKET

XLRN

XLRN

Acceleron
NASDAQ

Real-time Quotes | Nasdaq Last Sale

56.14
-0.11
-0.20%
After Hours: 56.14 0 0.00% 16:07 01/17 EST
OPEN
56.26
PREV CLOSE
56.25
HIGH
56.72
LOW
55.65
VOLUME
310.83K
TURNOVER
--
52 WEEK HIGH
56.90
52 WEEK LOW
37.01
MARKET CAP
2.98B
P/E (TTM)
-20.8497
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of XLRN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

XLRN News

  • The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares
  • Benzinga.1d ago
  • 2019 Review: Top Hedge Fund Stocks vs. Acceleron Pharma Inc (XLRN)
  • Insider Monkey.5d ago
  • The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx
  • Benzinga.01/10 12:13
  • Bristol-Myers Squibb Highlights Publishing Of Results For Pivotal Phase 3 Reblozyl MEDALIST Trial In New England Journal Of Medicine
  • Benzinga.01/09 11:59

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About XLRN

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.
More

Webull offers Acceleron Pharma Inc (XLRN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.